Table 2.
Association of Impaired Fasting Glucose vs Normoglycemia With Outcomes
| Outcome | Normoglycemia | Impaired Fasting Glucose | Hazard Ratio (95% CI) |
|---|---|---|---|
| No. of Events/No. at Risk (%) | |||
| Composite adverse renal outcomea | 314/5424 (5.8) | 221/3897 (5.7) | |
| Unadjusted model | 0.95 (0.80–1.14) | ||
| Adjusted model | 0.97 (0.81–1.16) | ||
| Worsening kidney functionb | 114/5424 (2.1) | 79/3897 (2.0) | |
| Unadjusted model | 0.91 (0.68–1.22) | ||
| Adjusted model | 1.02 (0.75–1.37) | ||
| Incident albuminuriac | 203/2691 (7.5) | 147/1928 (7.6) | |
| Unadjusted model | 1.01 (0.81–1.25) | ||
| Adjusted model | 0.98 (0.78–1.23) | ||
Adjusted model: age, sex, race, smoking status, systolic blood pressure, prior cardiovascular disease, body mass index, statin use, aspirin use, and trial treatment arm.
Defined by worsening kidney function or incident albuminuria.
In participants without CKD at baseline, worsening kidney function was defined by a decrease in the eGFR of 30% or more to a value of <60 mL/min/1.73 m2. In participants with CKD at baseline, worsening kidney function was defined by a decrease in the eGFR of 50% or more or the development of ESRD requiring long-term dialysis or kidney transplantation.
Defined for all study participants by a doubling of the ratio of urinary albumin/creatinine from <10 mg/g at baseline to >10 mg/g during follow-up.